Bryan Garnier - CAST SA (CAS) CAST - BUY | EUR4,7 Q3 2018 sales in line and strong Q4 in perspective

Report

Bryan Garnier

Gregory Ramirez

CAST - BUY | EUR4,7 Q3 2018 sales in line and strong Q4 in perspective

CAST - BUY | EUR4,7
Q3 2018 sales in line and strong Q4 in perspective

Q3 2018 was in line with expectations
Q4 2018 is to be helped by easy comps due to deal slippages
Management is confident for 2019
Buy reiterated

01/11/2018 2 EN

Underlying

CAST SA

Cast is engaged in the design, publishing and distribution of computer software programs. Co. also offers IT consulting and technical assistance for professional information systems. Co. operates in France, U.S.A., Belgium, Spain, Italy, Switzerland, and Germany.

See profile

FR0000072894 Euronext Paris France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gregory Ramirez

Other Reports on these Companies

GlobeNewsWire

Deloitte partners with CAST to launch a "Green IT by Design" offering

Deloitte partners with CAST to launch a "Green IT by Design" offering NEW YORK and PARIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Today Deloitte and CAST announced a new service offering – Green IT by Design, designed to help organizations define and rollout Digital Sobriety strategies, delivered by Deloitte and powered by software intelligence provided by CAST. The topic of Digital Sobriety has become increasingly important within the Corporate Social Responsibility framework and Digital Sobriety is now seen as a strategic priority for managing companies at all organization levels and across ...

October 20, 2022 October 20, 2022 1 EN

GlobeNewsWire

CAST expands ecosystem to help accelerate Application Modernization for Cloud

CAST expands ecosystem to help accelerate Application Modernization for Cloud NEW YORK and PARIS, June 09, 2022 (GLOBE NEWSWIRE) -- CAST, the leading provider of software intelligence, today announced the expansion of its ecosystem to help organizations migrating complex custom-built software to cloud. These business-critical applications are mostly designed for very different environments and need to be modernized when moving to cloud. Typically, there is no accurate intelligence about their actual architecture or what needs to change inside. The success and pace of the entire journey h...

June 9, 2022 June 9, 2022 1 EN

GlobeNewsWire

CAST revenue stable in Q1 as CAST confirms transition to annual subscriptions

CAST revenue stable in Q1 as CAST confirms transition to annual subscriptions Revenue in M€20222021Variation% TCC*T18,89,0-0,16-1,7 % * At current exchange rate NEW YORK and PARIS, May 03, 2022 (GLOBE NEWSWIRE) -- First quarter revenue amounted to €8.8 million, nearly same as in 2021, reflecting unfavorable comparison to Q1 2021, which was marked by a major transaction with a System Integrator amounting to nearly 20% of Q1 2021 software revenue. In addition, more than 90% of new business in the quarter was conducted on annual subscription or short-term license basis, in order to graduall...

May 3, 2022 May 3, 2022 1 EN

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Cinclus’ Q2 update focused on balance sheet items and a recap of corporate achievements. The company reported a cash position of SEK589m and operating expenses of SEK80.9m, up from the prior quarter - consistent with expectations given the Phase 3 trial ramp-up. With support from the Zentiva partne

13h / 43m 13h / 43m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Submits pre-NDA meeting, positive recruitment update

Egetis posted a positive US development update on Emcitate with 15 evaluable patients in the US ReTRIACt phase 3 study (vs 12 at previous update) and has submitted a pre-NDA meeting (Type B) request to the FDA, with plans to initiate the submission of the NDA for tiratricol (Emcitate) this year. As

August 18, 2025 August 18, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Faron is advancing bexmarilimab (BEX) into a registrational phase 2/3 trial in HR-MDS following a positive EOP2 meeting with the FDA. We view the feedback of broadly positive, as the trial design remains largely unchanged, with a single study expected to support approvals in both frontline and rela

August 18, 2025 August 18, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CAST - BUY | EUR4,7 Q3 2018 sales in line and strong Q4 in perspective

Deloitte partners with CAST to launch a "Green IT by Design" offering

CAST expands ecosystem to help accelerate Application Modernization for Cloud

CAST revenue stable in Q1 as CAST confirms transition to annual subscriptions

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Egetis: Submits pre-NDA meeting, positive recruitment update

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe